Arrowhead Pharma Enters Material Definitive Agreement

Ticker: ARWR · Form: 8-K · Filed: Jan 4, 2024 · CIK: 879407

Complexity: simple

Sentiment: neutral

Topics: material-agreement, corporate-action, strategic-partnership

TL;DR

**Arrowhead just signed a big deal, could be a game-changer.**

AI Summary

Arrowhead Pharmaceuticals, Inc. filed an 8-K on January 4, 2024, reporting an "Entry into a Material Definitive Agreement" as of January 2, 2024. This filing indicates a significant new contract or partnership for the company, which could impact its future revenue streams or operational strategy. For investors, this matters because material agreements often signal new business opportunities, collaborations, or changes in the company's financial outlook, potentially affecting stock valuation.

Why It Matters

This filing signals a new, significant business arrangement for Arrowhead Pharmaceuticals, Inc., which could lead to new revenue, expanded market reach, or strategic partnerships. Such agreements often drive future growth and can positively influence investor sentiment and stock price.

Risk Assessment

Risk Level: medium — While a material agreement can be positive, the specific details and financial implications are not disclosed in this initial 8-K, introducing uncertainty about its actual impact.

Analyst Insight

Investors should monitor Arrowhead Pharmaceuticals' future announcements for specific details regarding this 'Material Definitive Agreement' to assess its potential impact on the company's financials and strategic direction before making investment decisions.

Key Players & Entities

Forward-Looking Statements

FAQ

What is the specific nature of the 'Material Definitive Agreement' mentioned in the filing?

The 8-K filing, dated January 4, 2024, only states 'Entry into a Material Definitive Agreement' as of January 2, 2024, under Item 1.01. It does not provide specific details about the nature of the agreement, such as the parties involved, the terms, or the financial implications.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on January 2, 2024, which is the date of the 'Entry into a Material Definitive Agreement' as stated in the filing.

What is the trading symbol and exchange for Arrowhead Pharmaceuticals, Inc. common stock?

The trading symbol for Arrowhead Pharmaceuticals, Inc. common stock is ARWR, and it is registered on The Nasdaq Global Select Market, as indicated in the filing under 'Securities registered pursuant to Section 12(b) of the Act'.

What is the business address of Arrowhead Pharmaceuticals, Inc.?

The business address of Arrowhead Pharmaceuticals, Inc. is 177 E. Colorado Blvd, Suite 700, Pasadena, CA 91105, according to the 'BUSINESS ADDRESS' section of the filing.

Does this 8-K filing provide any financial statements or exhibits related to the material agreement?

The 8-K filing lists 'Financial Statements and Exhibits' under Item 9.01, but the provided text does not include the actual exhibits or financial statements themselves, only the item heading. Further review of the full filing would be needed to see if specific exhibits were attached.

Filing Stats: 709 words · 3 min read · ~2 pages · Grade level 11.9 · Accepted 2024-01-04 17:27:36

Key Financial Figures

Filing Documents

01 Entry into a Material Definitive Agreement

Item 1.01 Entry into a Material Definitive Agreement On January 2, 2024, Arrowhead Pharmaceuticals, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Jefferies LLC, BofA Securities, Inc. and Cowen and Company, LLC, as representatives of the several underwriters (the "Underwriters"), pursuant to which the Company agreed to issue and sell 15,790,000 shares of the Company's common stock (the "Shares"), par value $0.001 per share at an offering price of $28.50 per Share (the "Offering"). The Company estimates that net proceeds from the offering will be approximately $429.0 million, after deducting the Underwriters' discounts and commissions and estimated offering expenses payable by the Company. The Company intends to use the net proceeds from the Offering for research and development, general corporate expenses and working capital needs. The offering is being made pursuant to the Company's automatically effective shelf registration statement on Form S-3 (Registration No. 333-268665), which was filed and became automatically effective on December 5, 2022, as supplemented by a prospectus supplement, dated January 2, 2024, filed with the Securities and Exchange Commission on January 4, 2024. The offering is expected to close on January 5, 2024, subject to customary closing conditions. Pursuant to the Underwriting Agreement, the Company has agreed to indemnify the Underwriters against certain liabilities, including liabilities under the Securities Act of 1933, as amended, or to contribute to payments that the Underwriters may be required to make because of such liabilities. A copy of the Underwriting Agreement is attached as Exhibit 1.1 hereto and is incorporated herein by reference. The foregoing descriptions of the Underwriting Agreement do not purport to be complete and are qualified in their entirety by reference to such exhibits. A copy of the opinion of Gibson, Dunn & Crutcher LLP relating to the validity of t

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 1.1 Underwriting Agreement, dated as of January 2, 2024, among Arrowhead Pharmaceuticals, Inc. and Jefferies LLC, BofA Securities, Inc. and Cowen and Company, LLC, as representatives of the underwriters named therein. 5.1 Opinion of Gibson, Dunn & Crutcher LLP 23.1 Consent of Gibson, Dunn & Crutcher LLP (contained in Exhibit 5.1)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: January 4, 2024 ARROWHEAD PHARMACEUTICALS, INC. By: /s/ Kenneth Myszkowski Kenneth Myszkowski Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing